GlassScriptPhysician profile
Laura Durell
NPI 1689602138
$9,038.75
in general payments reported to CMS, 2019-2025
30 companies · $2,269 in 2025
The $2,269 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,279 · 2022: $1,627 · 2023: $1,835 · 2024: $2,028 · 2025: $2,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,774.34 |
| Education | $357.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,089.40 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $715.51 | 2021-2025 | |
| Pfizer INC. | $629.26 | 2021-2025 | |
| Janssen Biotech, INC. | $491.21 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Dermavant Sciences, INC. | $394.62 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $391.08 | 2021-2025 | Ilumya |
| Ucb, INC. | $361.05 | 2021-2025 | Bimzelx |
| Incyte Corporation | $347.42 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $328.57 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $315.22 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $313.62 | 2021-2025 | |
| Amgen INC. | $296.35 | 2021-2025 | Otezla, Enbrel, Otezla |
| Mayne Pharma Commercial LLC | $223.98 | 2023-2025 | |
| Lilly USA, LLC | $207.03 | 2021-2025 | Ebglyss, Taltz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $186.68 | 2022-2025 | Sotyktu |
| Almirall LLC | $181.53 | 2021-2024 | Seysara |
| Allergan, INC. | $178.11 | 2021-2022 | |
| Epi Health, LLC | $142.12 | 2021-2022 | |
| Biofrontera INC. | $130.99 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $116.16 | 2025 | Sofdra |
| Organon LLC | $93.86 | 2025 | Nexplanon, Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $58.75 | 2021 | |
| Arcutis Biotherapeutics, INC. | $55.25 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $52.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.09 | 2023-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $20.63 | 2024 | Ycanth |
| Fidia Pharma USA INC. | $15.43 | 2024 | Hymovis, Triluron, Hyalgan |
| Kerecis Limited | $11.26 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Durell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.